A Case-based Exercise in Getting Comfortable with Insulin Therapy
EndocrinologyUsing Insulin to Bring Patients Safely to Target
1.0 AMA PRA Category 1 Credit(s) ™ 1.0 AANP Contact Hours 0.75 Pharmacology
December 20, 2018
The accreditation for this activity has expired.
Primary Audience:
Primary Care Physicians; Nurse Practitioners; Physician Assistants and other clinicians managing patients with Diabetes
Relevant Terms:
Type 2 diabetes; insulin
Davida Kruger
Davida F. Kruger, MSN, APN-BC, BC-ADM
Certified Nurse Practitioner Henry Ford Health System Division of Endocrinology, Diabetes, Bone and Mineral Disease
Detroit, MI
Bio
Ms. Kruger has been a certified nurse practitioner in diabetes at Henry Ford Health System in Detroit, MI, for more than 35 years. She earned her Master of Science in Nursing degree from Wayne State University in Detroit and her Bachelor of Science in Nursing degree from Boston College, in Boston, MA. Her role includes both clinical practice and research, and she is board-certified in both primary care and advanced diabetes management. Ms. Kruger has been a co-investigator on numerous studies of diabetes interventions and care, including the National Institutes of Health-funded multicenter EDIC and ACCORD trials. She lectures extensively throughout the United States on maximizing outcomes in diabetes and diabetes management.
She is a past Chair of the American Diabetes Association (ADA) Research Foundation and has served on the ADA Research Policy Committee. She is also an ADA Past President, Health Care and Education. She has published more than 50 abstracts, articles, and chapters on diabetes management and authored the 2006 second edition of The Diabetes Travel Guide. She has also served as editor-in-chief of two American Diabetes Association (ADA) journals, Diabetes Spectrum and Clinical Diabetes.
Mark Stolar, MD
Mark Stolar, MD
Associate Professor of Clinical Medicine
Feinberg School of Medicine
Northwestern University
Chicago, IL
Bio
Mark Stolar, MD
Associate Professor of Clinical Medicine
Feinberg School of Medicine
Northwestern University
Chicago, IL
Mark Stolar, MD, is Associate Professor of Clinical Medicine, General Internal Medicine, and Geriatrics at Northwestern University Feinberg School of Medicine in Chicago, Illinois. Dr Stolar received his medical degree from the University of Illinois, Chicago. He completed his fellowship in Endocrinology at the Northwestern University Medical School and his residency in internal medicine at Lutheran General Hospital. Dr Stolar is board certified in endocrinology, diabetes, and metabolism, and internal medicine.
Dr Stolar’s academic interests include diabetes, lipid disorders, and thyroid disease. A highly regarded speaker, he is actively involved in physician education in the area of diabetes and CV disease and has both written and presented in the US and internationally in those areas. He is currently president of the Endocrine Fellows Foundation and is actively involved in enhancing career opportunities for trainees in Endocrinology.
Javier Morales, MD, FACP, FACE
Javier Morales, MD, FACP, FACE
Javier Morales, MD, FACP, FACE
Clinical Associate Professor of Medicine
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell University
Vice President
Advanced Internal Medicine Group, P.C.
East Hills, NY
Bio
Javier Morales, MD, FACP, FACE
Clinical Associate Professor of Medicine
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell University
Vice President
Advanced Internal Medicine Group, P.C.
East Hills, NY
Dr. Morales is in private practice with the Advanced Internal Medicine Group in East Hills, NY. After having graduated from UMDNJ-NJ Medical School, his medical training included residencies at Memorial Sloan-Kettering Cancer Center and North Shore University Hospital where he served as Chief Medical Resident. In addition to numerous publications, he has served as principal investigator for several different studies and clinical trials. He is active in the educational sector and presents at continuing education symposia both nationally and internationally. Dr. Morales serves as clinical instructor for several nurse practitioner programs, physician assistant programs, and the internal medicine residency program at Northwell Health at North Shore University Hospital and Winthrop University Hospital. He is a also Clinical Assistant Professor of Medicine at the Northwell School of Medicine at Hofstra University.
| 1. | Identify the barriers between clinicians and patients to discussing and initiating earlier insulin therapy for diabetes management | 2. | Discuss currently available basal and ultrabasal insulins and their pharmacokinetic/ pharmacodynamic profiles |
| 3. | Describe how best to initiate, utilize and intensify insulin therapy in patients with diabetes while incorporating treatment guidelines and unique patient needs | 4. | Integrate strategies to improve the patient experience with, and adherence to, insulin therapy |
| 1. | Identify the barriers between clinicians and patients to discussing and initiating earlier insulin therapy for diabetes management |
| 2. | Discuss currently available basal and ultrabasal insulins and their pharmacokinetic/ pharmacodynamic profiles |
| 3. | Describe how best to initiate, utilize and intensify insulin therapy in patients with diabetes while incorporating treatment guidelines and unique patient needs |
| 4. | Integrate strategies to improve the patient experience with, and adherence to, insulin therapy |
Planning Committee
Gregg Sherman, MD
Chief Medical Officer/Course Director
National Association for Continuing Education
Plantation, FL
Sandy Bihlmeyer, M.Ed.
National Association for Continuing Education
Plantation, FL
Michelle Frisch, MPH, CHCP
National Association for Continuing Education
Plantation, FL
Sheila Lucas, CWEP
National Association for Continuing Education
Plantation, FL
Joshua Kilbridge, President
Kilbridge Associates
San Francisco, CA
PROGRAM OVERVIEW:
Type 2 diabetes mellitus (T2DM) is a major cause of morbidity and mortality in the United States, and its prevalence has been increasing. The disease is characterized by progressive failure of pancreatic β-cell function, leading to increasing difficulty in maintaining glycemic control. Even with multiple oral antidiabetic drugs, many patients need insulin therapy to achieve and maintain glycated hemoglobin (HbA1C) targets.
Early initiation of insulin therapy can reduce morbidity in patients with T2DM, but in practice, insulin therapy is underused. Using video clips taken from a live studio broadcast presented as part of Emerging Challenges in Primary Care 2018, this activity will identify the barriers of clinicians and patients for early initiation of insulin therapy, the current available basal and ultrabasal insulins, and how to develop strategies for initiation and intensification of therapies and improve patient adherence.
DISCLOSURE POLICY STATEMENT:
It is the policy of NACE to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. NACE assesses conflict of interest with its faculty, planners and managers of CME activities. Conflicts of interest that are identified are resolved by reviewing that presenter's content for fair balance and absence of bias, scientific objectivity of studies utilized in this activity, and patient care recommendations.
While NACE endeavors to review faculty content, it remains the obligation of each physician or other healthcare practitioner to determine the applicability or relevance of the information provided from this course in his or her own practice.
DISCLOSURE OF CONFLICTS OF INTEREST:
Faculty
Mark Stolar, MD serves on the speakers bureau for AstraZeneca.
Javier Morales, MD, FACP, FACE serves on the speakers bureau and as a consultant for Lilly, Novo Nordisk, Janssen, and Abbott.
Davida F. Kruger, MSN, APN-BC, BC-ADM serves on the advisory board for Novo Nordisk, Abbott, Eli Lilly and Company, Sanofi US, Janssen, Dexcom, and Intarcia. Davida also serves on the speakers bureau for Janssen, Valeritas, AZ, BI/Lilly, Novo Nordisk, Dexcom, Lilly, Abbott, and Insulet. Additionally, she serves on the grants research team for AZ, Eli Lilly, Novo Nordisk, Hemsley Foundation, Dexcom, Lexicon, Abbott and has stock in Dexcom.
Planning Committee
Gregg Sherman, MD, has no real or apparent conflicts of interest to report.
Sandy Bihlmeyer, M.Ed., has no real or apparent conflicts of interest to report.
Michelle Frisch, MPH, CHCP, has no real or apparent conflicts of interest to report.
Sheila Lucas, CWEP, has no real or apparent conflicts of interest to report.
Josh Kilbridge has no real or apparent conflicts of interest to report.
DISCLOSURE OF UNLABELED USE
NACE requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
DISCLAIMER
The opinions expressed during the educational activity are those of the faculty and do not necessarily represent the views of NACE. The information is presented for the purpose of advancing the attendees' professional development.
ACCREDITATION STATEMENT
The National Association for Continuing Education is accredited by the ACCME to provide continuing medical education for physicians.
National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Academy of Nurse Practitioners. AANP Provider Number 121222.
This CME activity was planned and produced in accordance with the ACCME Essentials and the AANP CE Standards and Policies and AANP Commercial Support Standards.
For CME questions, please contact: NACE at info@naceonline.com
Contact this CME provider for privacy and confidentiality policy statement information at:
https://www.naceonline.com/privacy_policy.php
CREDIT DESIGNATION STATEMENT
NACE designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim credit commensurate with the extent of their participation in the activity.
National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Academy of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 1.0 contact hours of continuing education (which includes 0.75 hours of pharmacology).
TO OBTAIN CME CREDITS
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the post-test and activity evaluation.
- Physicians who successfully complete the post-test and evaluation will receive CME credit.
- Nurse Practitioners who successfully complete the post-test and evaluation will receive AANP CE credit.
- You must score 60% or higher on the post-test to receive credit for this activity.
- All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
COURSE FORMAT/MEDIUM: Internet CME Activity
ESTIMATED TIME TO COMPLETE: 60 minutes
ACKNOWLEDGEMENT
This activity is sponsored by the National Association for Continuing Education.
This educational activity is supported by an independent educational grant from Sanofi US.
If you have any questions regarding this activity, send an email to info@naceonline.com.
Copyright © 2018 National Association for Continuing Education. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of NACE is prohibited.
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 and above Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6+ for Mac OSX 10.7 and above For video playback, install the latest version of Flash or Quicktime. | Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above |
